# TOVX catalysts: Theriva Biologics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tovx/catalysts

> Theriva Biologics, Inc. (TOVX) has 2 upcoming catalysts. The next is the zabilugene almadenorepvec trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for TOVX?

Theriva Biologics, Inc. (TOVX) has 2 upcoming catalysts. The next is the zabilugene almadenorepvec trial start, Q1 2027. SEC Form 10-Q: "Based on our current plans, we expect that our current cash will be sufficient to fund operations into the first quarter of 2027 and will only be sufficient to cover overhead costs, commence an approved Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period, conduct exploratory VCN-01 manufacturing scale-up activities, complete regulatory interactions regarding a proposed pivotal clinical trial of VCN-01 in retinoblastoma, and undertake limited preclinical studies supporting VCN-01 and VCN-12, the first candidate from our VCN-X discovery program." [Calendar and source filings](https://sec-api.dev/companies/tovx/catalysts)

Source: SEC Form 10-Q, accession 0001104659-26-093786, https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm (retrieved 2026-11-12). Last confirmed 2026-08-11. Cite: https://sec-api.dev/companies/tovx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Theriva Biologics, Inc. |
| Ticker | TOVX (NYSE) |
| SEC CIK | 894158 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tovx |

## Cash runway

Cash $8.5M as of 2026-09-30; quarterly burn $2.9M; about 8.9 months of runway at that rate (XBRL company facts, accession 0001104659-26-125918).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [Zabilugene almadenorepvec FDA approval](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | completed, approved | "In September 2022, we received approval from the FDA to proceed with the Phase 2 clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (mPDAC)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/894158/000110465925109828/tmb-20250930x10q.htm)) |
| April 23, 2024 | [Theriva Biologics, Inc. topline data readout](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed, positive | "On April 23, 2024, we announced positive topline data from this study, with agreement by the study Monitoring Committee that the study had a positive outcome." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm)) |
| April 23, 2024 | [Zabilugene almadenorepvec topline data readout](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX | refractory retinoblastoma | completed, positive | "On April 23, 2024, we announced positive topline data from the investigator sponsored Phase 1 Trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/894158/000141057824001850/tmb-20240930x10q.htm)) |
| November 12, 2024 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/tm2426982d2_ex99-1.htm)) |
| March 6, 2025 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_ex99-1.htm)) |
| Q2 2025 | [Zabilugene almadenorepvec topline data readout](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | scheduled | "2024 and topline clinical outcomes data are anticipated in Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_ex99-1.htm)) |
| May 7, 2025 | [Theriva (theriva) topline data readout](https://sec-api.dev/pdufa/theriva) | TOVX | cancer and related diseases in areas of high unmet need, today | completed, positive | "MD, May 07, 2025 - Theriva™ Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/tm2514050d1_ex99-1.htm)) |
| May 7, 2025 | [Zabilugene almadenorepvec topline data readout](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | completed, positive | "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating our lead product candidate VCN-01 (zabilugene almadenorepvec) plus SoC chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with mPDAC for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm)) |
| May 14, 2025 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/tm2514864d1_ex99-1.htm)) |
| August 11, 2025 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/tm2522967d1_ex99-1.htm)) |
| November 12, 2025 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/tm2530928d1_ex99-1.htm)) |
| March 12, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports Full-Year 2025 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926026765/tm268491d1_ex99-1.htm)) |
| May 5, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports First Quarter 2026 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm)) |
| August 11, 2026 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_ex99-1.htm)) |
| August 11, 2026 | [Zabilugene almadenorepvec trial start](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | completed | "As recently announced, the first patients have been dosed in the VIRAGE2 Phase 2a clinical trial entitled "A" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_ex99-1.htm)) |
| November 12, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926125912/tm2629526d1_ex99-1.htm)) |
| Q1 2027 | [Zabilugene almadenorepvec trial start](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | scheduled | "Based on our current plans, we expect that our current cash will be sufficient to fund operations into the first quarter of 2027 and will only be sufficient to cover overhead costs, commence an approved Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period, conduct exploratory VCN-01 manufacturing scale-up activities, complete regulatory interactions regarding a proposed pivotal clinical trial of VCN-01 in retinoblastoma, and undertake limited preclinical studies supporting VCN-01 and VCN-12, the first candidate from our VCN-X discovery program." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm)) |
| Q3 2027 | [Zabilugene almadenorepvec interim data readout](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | scheduled | "- VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926125912/tm2629526d1_ex99-1.htm)) |

## Drugs

- [Theriva (theriva)](https://sec-api.dev/pdufa/theriva): cancer and related diseases in areas of high unmet need, today
- [Zabilugene almadenorepvec](https://sec-api.dev/pdufa/zabilugene-almadenorepvec): metastatic pancreatic ductal adenocarcinoma, mpdac for whom gemcitabine/nab-paclitaxel, refractory retinoblastoma conducted, refractory retinoblastoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tovx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TOVX catalysts: Theriva Biologics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tovx/catalysts

```bibtex
@misc{secapidev_companies_tovx_catalysts_20261116,
  title        = {TOVX catalysts: Theriva Biologics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tovx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tovx_catalysts_20261116","title":"TOVX catalysts: Theriva Biologics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tovx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
